User:Mr. Ibrahem/Liraglutide
Clinical data | |
---|---|
Trade names | Victoza, Saxenda, others |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous |
Drug class | GLP-1 receptor agonist[1] |
Legal status | |
Legal status | |
Chemical and physical data | |
Formula | C172H265N43O51 |
Molar mass | 3751.262 g·mol−1 |
3D model (JSmol) | |
| |
|
Liraglutide, sold under the brand name Victoza among others, is a medication used to treat diabetes mellitus type 2 and obesity.[1] In diabetes it is a less preferred agent compared to metformin.[1][3] Its effects on long-term health outcomes like heart disease and life expectancy are unclear.[1] In obesity if after 12 weeks less than 5% of body weight is lost it is recommended the medication be stopped.[4] It is given by injection under the skin.[1]
Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection.[1] Other serious side effects may include medullary thyroid cancer, angioedema, pancreatitis, gallbladder disease, and kidney problems.[1] Use in pregnancy and breastfeeding is of unclear safety.[1] Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics.[1] It works by increasing insulin release from the pancreas and decreases excessive glucagon release.[1]
Liraglutide was approved for medical use in Europe in 2009 and in the United States in 2010.[5][6] A month supply in the United Kingdom costs the NHS about £79 as of 2019.[4] In the United States the wholesale cost of this amount is about US$98.[7] In 2017, it was the 163rd most commonly prescribed medication in the United States, with more than three million prescriptions.[8][9]
References
[edit]- ^ a b c d e f g h i j k l "Liraglutide Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 23 March 2019. Retrieved 23 March 2019.
- ^ Cite error: The named reference
WHO2020DDD
was invoked but never defined (see the help page). - ^ Shyangdan D, Cummins E, Royle P, Waugh N (May 2011). "Liraglutide for the treatment of type 2 diabetes". Health Technol Assess. 15 Suppl 1: 77–86. doi:10.3310/hta15suppl1/09. PMID 21609656.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 685. ISBN 9780857113382.
- ^ "Liraglutide". European Medicines Agency. 17 September 2018. Archived from the original on 23 March 2019. Retrieved 23 March 2019.
- ^ "DailyMed - liraglutide injection". dailymed.nlm.nih.gov. Archived from the original on 27 March 2021. Retrieved 23 March 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Liraglutide - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.